A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar […]

1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in

Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term

The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file

There is a rule in corporate strategy that says any resource your competitor needs, and that you control, is a

Top-Level Key Takeaways 1. What the Rule of Three Actually Is (and What It Isn’t) 1.1 The Economic Premise The

1. Why the Generic Market Runs on Partnerships, Not Margins Generics and biosimilars filled 90% of all U.S. prescriptions dispensed

Executive Framing: The Cost Problem That Waste Built {#executive-framing} Generic drugs fill roughly nine out of every ten prescriptions dispensed

Section 1: The Modern API Manufacturing Landscape 1.1 What an API Is, and Why Its Manufacturing Process Is a Core